目的 探討復(fù)方甘草酸苷聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎的臨床療效。方法 選取2010年2月-2014年10月中國人民解放軍第二五一醫(yī)院消化內(nèi)科收治的潰瘍性結(jié)腸炎患者260例,隨機(jī)分為對照組和治療組,每組各130例。對照組患者口服柳氮磺吡啶腸溶片,1.0 g/次,4次/d。治療組在對照組治療基礎(chǔ)上口服復(fù)方甘草酸苷片,2片/次,3次/d。兩組均連續(xù)治療4周。觀察兩組的臨床療效,同時比較治療前后兩組臨床活動指數(shù)、血清白介素-6(IL-6)、白介素-8(IL-8)、腫瘤壞死因子-α(TNF-α)的變化情況。觀察兩組患者的不良反應(yīng)和1年內(nèi)的復(fù)發(fā)情況。結(jié)果 治療后,對照組和治療組的總有效率分別為80.00%、96.15%,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,兩組臨床活動指數(shù)、IL-6、IL-8、TNF-α水平均顯著降低,同組治療前后差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的下降程度優(yōu)于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組1年復(fù)發(fā)率明顯低于對照組,平均復(fù)發(fā)次數(shù)明顯少于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方甘草酸苷聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎具有較好的臨床療效,可顯著抑制炎癥反應(yīng),同時還可降低遠(yuǎn)期復(fù)發(fā)率,具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of compound glycyrrhizin combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (260 cases) with ulcerative colitis in Department of Gastroenterology of the 251^st Hospital of PLA from February 2010 to October 2014 were randomly divided into control (n=130) and treatment (n=130) groups. The patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 1.0 g/time, four times daily. The patients in the treatment group were po administered with Compound Glycyrrhizin Tablets on the basis of the control group, 2 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the changes of clinical activity indexes, IL-6, IL-8, and TNF-α in two groups were compared. The adverse reactions and relapse within 1 year in two groups were observed. Results After treatment, the efficacies in the control and treatment groups were 80.00% and 96.15%, respectively, and there were differences between two groups (P < 0.05). After treatment, clinical activity indexes, IL-6, IL-8, and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The recurrence rate within 1 year and the average numbers of recurrence in the treatment group were obviously lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Compound glycyrrhizin combined with sulfasalazine has clinical curative effect in treatment of ulcerative colitis, and can inhibit the inflammatory response, also can reduce long-term recurrence rate, which has a certain clinical application value.